Type to search

Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers | Pharmtech Focus
FDA Approves First NGS-based Companion Diagnostic to Aid in Selecting Non-small Cell Lung Cancer Patients With HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment With ENHERTU | Pharmtech Focus
FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue | Pharmtech Focus